Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Fiorillo, G.; Ibba, L.; Gargiulo, L.; Vignoli, C.A.; Alfano, A.; Cortese, A.; Toso, F.; Orsini, D.; Iacovelli, P.; Frascione, P.; et al. Effectiveness and safety of anti-IL-23 and anti-IL-17 biological therapies for psoriasis in elderly patients: Real-world experience from two Italian hospitals. J. Eur. Acad. Dermatol. Venereol. 2023, 37, e1444–e1446. [Google Scholar] [CrossRef]
- Mastorino, L.; Dapavo, P.; Susca, S.; Cariti, C.; Siliquini, N.; Verrone, A.; Stroppiana, E.; Ortoncelli, M.; Quaglino, P.; Ribero, S. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. J. Dtsch. Dermatol. Ges. 2023, 22, 34–42. [Google Scholar] [CrossRef]
- Armstrong, A.W.; Read, C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA 2020, 323, 1945–1960. [Google Scholar] [CrossRef]
- Raudonis, T.; Gliebute, A.; Grigaityte, A.G.; Lukosiunaite, Z.; Karmaziene, T.; Grigaitiene, J. A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology. Medicina 2020, 56, 275. [Google Scholar] [CrossRef]
- Hägg, D.; Eriksson, M.; Sundström, A.; Schmitt-Egenolf, M. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS ONE 2013, 8, e63619. [Google Scholar] [CrossRef] [PubMed]
- Kan, J.; Chen, Q.; Tao, Q.; Wu, L.; Wang, D.; Jiang, Z.; Du, X.; Gu, Y.; Gu, Y. Prospective evaluation of cardiovascular risk and mortality in patients with psoriasis: An American population-based study. Exp. Dermatol. 2024, 33, e15010. [Google Scholar] [CrossRef]
- Shani, U.; Ben-Shabat, N.; Qassem, R.; Lahat, A.; Omar, M.; Savin, E.; Dotan, A.; Patt, Y.S.; Fisher, L.; Zacay, G.; et al. The association between psoriasis, psoriasis severity, and inflammatory bowel disease: A population-based analysis. Therap. Adv. Gastroenterol. 2024, 17, 17562848241227037. [Google Scholar] [CrossRef]
- Clinical Review Report: Guselkumab (Tremfya): (Janssen Inc.): Indication: For the Treatment of Adult Patients with Moderate-to-Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy [Internet]; Canadian Agency for Drugs and Technologies in Health: Ottawa, ON, Canada, March 2018. Available online: https://www.ncbi.nlm.nih.gov/books/NBK534046/ (accessed on 31 January 2024).
- Brunasso, A.M.G.; Burlando, M.; Amoruso, F.; Arancio, L.; Malara, G.; Manzo, R.; Montesu, M.A.; Caldarola, G. Risankizumab: Daily Practice Experience of High Need Patients. Biomedicines 2023, 11, 1769. [Google Scholar] [CrossRef] [PubMed]
- Strober, B.; Greenberg, J.D.; Karki, C.; Mason, M.; Guo, N.; Hur, P.; Zhao, Y.; Herrera, V.; Lin, F.; Lebwohl, M. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: Real-world data from the Corrona Psoriasis Registry. BMJ Open 2019, 9, e027535. [Google Scholar] [CrossRef]
- Daudén, E.; Vidal, D.; Romero, A.; Bordel, M.T.; Rivera, R.; Márquez, J.; Zamora, E.; Martinez, L.; Ocaña, M.J.; Vila, C.; et al. Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain. Actas Dermosifiliogr. 2024, 115, T1–T9. [Google Scholar] [CrossRef]
- Martin, G.; Young, M.; Aldredge, L. Recommendations for Initiating Systemic Therapy in Patients with Psoriasis. J. Clin. Aesthet. Dermatol. 2019, 12, 13–26. [Google Scholar] [PubMed]
- Darwin, E.; Lebwohl, M.; Han, G. Biologic Vs Conventional Therapies: Comparing Risk of Psoriasis-Associated Comorbidities. J. Drugs Dermatol. 2023, 22, 621–622. [Google Scholar] [CrossRef]
- Zhu, B.; Jing, M.; Yu, Q.; Ge, X.; Yuan, F.; Shi, L. Treatments in psoriasis: From standard pharmacotherapy to nanotechnology therapy. Postep. Dermatol. Alergol. 2022, 39, 460–471. [Google Scholar] [CrossRef] [PubMed]
- Pavia, G.; Gargiulo, L.; Spinelli, F.; Avagliano, J.; Valenti, M.; Borroni, R.G.; Costanzo, A.; Narcisi, A. Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab. J. Eur. Acad. Dermatol. Venereol. 2022, 36, e502–e505. [Google Scholar] [CrossRef]
- Deng, S.; Zhou, G.; Li, X.; Zhang, G.; Hu, K.; Lu, Y.; Li, J.; Liu, Y.; Zhou, G.; Zhang, M.; et al. The impacts of biologic treatment on metabolic profiling in psoriasis. Exp. Dermatol. 2024, 33, e15011. [Google Scholar] [CrossRef] [PubMed]
- Timis, T.L.; Beni, L.; Florian, I.A.; Orăsan, M.; Orăsan, R.I. Prevalence of metabolic syndrome and chronic inflammation in psoriasis before and after biologic therapy: A prospective study. Med. Pharm. Rep. 2023, 96, 368–383. [Google Scholar] [CrossRef]
- Valenti, M.; Pavia, G.; Gargiulo, L.; Facheris, P.; Sanna, F.; Borroni, R.G.; Costanzo, A.; Narcisi, A. Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: Long-term safety in a single- center real-life population. J. Dermatol. Treat. 2022, 33, 1638–1642. [Google Scholar] [CrossRef]
- Shear, N.H.; Betts, K.A.; Soliman, A.M.; Joshi, A.; Wang, Y.; Zhao, J.; Gisondi, P.; Sinvhal, R.; Armstrong, A.W. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. J. Am. Acad. Dermatol. 2021, 85, 572–581. [Google Scholar] [CrossRef]
- Gisondi, P.; Fargnoli, M.C.; Amerio, P.; Argenziano, G.; Bardazzi, F.; Bianchi, L.; Chiricozzi, A.; Conti, A.; Corazza, M.; Costanzo, A.; et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital. J. Dermatol. Venerol. 2022, 157 (Suppl. S1), 1–78. [Google Scholar] [CrossRef]
- Mastorino, L.; Cariti, C.; Susca, S.; Siliquini, N.; Verrone, A.; Stroppiana, E.; Ortoncelli, M.; Dapavo, P.; Quaglino, P.; Ribero, S. Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis. Exp. Dermatol. 2023, 32, 1591–1594. [Google Scholar] [CrossRef]
- Fiocchi, M.; Zagni, E.; Colombo, D. Psoriasis: Gender perspective on disease characteristics and treatment. Ital. J. Gend.-Specif. Med. 2021, 7, 164–168. [Google Scholar] [CrossRef]
- Guillet, C.; Seeli, C.; Nina, M.; Maul, L.V.; Maul, J.T. The impact of gender and sex in psoriasis: What to be aware of when treating women with psoriasis. Int. J. Women’s Dermatol. 2022, 8, e010. [Google Scholar] [CrossRef]
- Menter, A.; Bhutani, T.; Ehst, B.; Elewski, B.; Jacobson, A. Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis. Dermatol. Ther. 2022, 12, 1289–1302. [Google Scholar] [CrossRef]
- Ibba, L.; Gargiulo, L.; Alfano, A.; Ingurgio, R.C.; Narcisi, A.; Costanzo, A.; Valenti, M. Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: A real-life retrospective study. J. Dermatol. Treat. 2023, 34, 2199108. [Google Scholar] [CrossRef]
- Loft, N.; Egeberg, A.; Rasmussen, M.K.; Bryld, L.E.; Nissen, C.V.; Dam, T.N.; Ajgeiy, K.K.; Iversen, L.; Skov, L. Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: A nationwide study. J. Eur. Acad. Dermatol. Venereol. 2022, 36, 1284–1291. [Google Scholar] [CrossRef]
- Poulsen, A.S.K.; Thomsen, S.F.; Vinkel, C.; Ghazanfar, M.N.; Wulf-Johansson, H.; Bonne, R.; Larsen, R. Fluctuations in serum levels of adalimumab and infliximab in patients on stable treatment for psoriasis. Dermatol. Ther. 2020, 33, e13497. [Google Scholar] [CrossRef]
- Menter, A.; Armstrong, A.; Van Voorhees, A.; Liu, C.; Jacobson, A. Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics. Dermatol. Ther. 2020, 10, 615–621. [Google Scholar] [CrossRef]
- Menter, A.; Strober, B.E.; Kaplan, D.H.; Kivelevitch, D.; Prater, E.F.; Stoff, B.K.; Armstrong, A.W.; Connor, C.; Cordoro, K.M.; Davis, D.M.R.; et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 2019, 80, 1029–1072. [Google Scholar] [CrossRef] [PubMed]
- McLean, R.R.; Sima, A.P.; Beaty, S.; Jones, E.A.; Eckmann, T.; Low, R.; McClung, L.; Spitzer, R.L.; Stark, J.; Armstrong, A. Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry. Dermatol. Ther. 2023, 13, 2753–2768. [Google Scholar] [CrossRef] [PubMed]
- Liau, M.M.; Oon, H.H. Therapeutic drug monitoring of biologics in psoriasis. Biologics 2019, 13, 127–132. [Google Scholar] [CrossRef] [PubMed]
- Karczewski, J.; Poniedziałek, B.; Rzymski, P.; Adamski, Z. Factors affecting response to biologic treatment in psoriasis. Dermatol. Ther. 2014, 27, 323–330. [Google Scholar] [CrossRef]
- Warren, R.B.; Smith, C.H.; Yiu, Z.Z.N.; Ashcroft, D.M.; Barker, J.N.W.N.; Burden, A.D.; Lunt, M.; McElhone, K.; Ormerod, A.D.; Owen, C.M.; et al. Differential drug survival of biologic therapies for the treatment of psoriasis: A prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J. Investig. Dermatol. 2015, 135, 2632–2640. [Google Scholar] [CrossRef]
- Reich, K.; Gordon, K.; Strober, B.; Armstrong, A.W.; Miller, M.; Shen, Y.K.; You, Y.; Han, C.; Yang, Y.W.; Foley, P.; et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: Results from VOYAGE 1 and VOYAGE 2. Br. J. Dermatol. 2021, 185, 1146–1159. [Google Scholar] [CrossRef]
- Kotb, I. Evidence for the long-term efficacy and safety of guselkumab. Br. J. Dermatol. 2021, 185, 1087–1088. [Google Scholar] [CrossRef]
- Kang, D.H.; Lew, B.L.; Kwon, S.H. Incidence of New-Onset Inflammatory Bowel Disease, Oral and Gastrointestinal Candidiasis, Herpes Zoster, Pulmonary Tuberculosis, and Major Cardiovascular Events in Patients with Moderate-to-Severe Psoriasis Exposed to Biologics. J. Clin. Med. 2023, 12, 7653. [Google Scholar] [CrossRef] [PubMed]
- Nogueira, M.; Warren, R.B.; Torres, T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis—Time for a paradigm change. J. Eur. Acad. Dermatol. Venereol. 2021, 35, 824–834. [Google Scholar] [CrossRef] [PubMed]
- Adelzadeh, L.; Jourabchi, N.; Wu, J.J. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. J. Eur. Acad. Dermatol. Venereol. 2014, 28, 846–852. [Google Scholar] [CrossRef]
- Kridin, K.; Zirpel, H.; Mruwat, N.; Ludwig, R.J.; Thaci, D. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors—A population-based study. J. Eur. Acad. Dermatol. Venereol. 2023, 37, 2319–2326. [Google Scholar] [CrossRef]
- Gelfand, J.M.; Neimann, A.L.; Shin, D.B.; Wang, X.; Margolis, D.J.; Troxel, A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 2006, 296, 1735–1741. [Google Scholar] [CrossRef] [PubMed]
- Samarasekera, E.J.; Neilson, J.M.; Warren, R.B.; Parnham, J.; Smith, C.H. Incidence of cardiovascular disease in individuals with psoriasis: A systematic review and meta-analysis. J. Investig. Dermatol. 2013, 133, 2340–2346. [Google Scholar] [CrossRef]
- Wang, X.; Kaiser, H.; Kvist-Hansen, A.; McCauley, B.D.; Skov, L.; Hansen, P.R.; Becker, C. IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis. Int. J. Mol. Sci. 2022, 23, 555. [Google Scholar] [CrossRef] [PubMed]
- Gelfand, J.M.; Shin, D.B.; Duffin, K.C.; Armstrong, A.W.; Blauvelt, A.; Tyring, S.K.; Menter, A.; Gottlieb, S.; Lockshin, B.N.; Simpson, E.L.; et al. A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). J. Investig. Dermatol. 2020, 140, 1784–1793. [Google Scholar] [CrossRef] [PubMed]
- Strober, B.; Leonardi, C.; Papp, K.A.; Mrowietz, U.; Ohtsuki, M.; Bissonnette, R.; Ferris, L.K.; Paul, C.; Lebwohl, M.; Braun, D.K.; et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J. Am. Acad. Dermatol. 2017, 76, 432–440. [Google Scholar] [CrossRef] [PubMed]
Number of Patients | 40 |
---|---|
Male, n (%) | 29 (72.50) |
Age (years), mean ± SD * | 55.80 ± 13.82 |
Disease duration (years), mean ± SD | 20.33 ± 15.27 |
BMI **, mean ± SD | 29.27 ± 10.19 |
Obese, n (%) | 5 (12.50) |
Cardiometabolic comorbidities, n (%) | 10 (25.00) |
Personal history of malignancies, n (%) | 1 (2.50) |
Latent tuberculosis infection, n (%) | 0 (0.00) |
Hepatitis C, n (%) | 0 (0.00) |
Hepatitis B, n (%) | 1 (2.50) |
PsA ***, n (%) | 8 (20.00) |
≥1 Difficult-to-treat areas, n (%) | 28 (70.00) |
PASI **** baseline, mean ± SD | 31.60 ± 2.57 |
Bio-naïve, n (%) | 33 (82.50) |
Anti-IL *****-23 agents | |
Risankizumab, n (%) | 21 (52.50) |
Guselkumab, n (%) | 4 (10.00) |
Tildrakizumab, n (%) | 1 (2.50) |
Anti-IL-17 agents | |
Ixekizumab, n (%) | 5 (12.50) |
Secukinumab, n (%) | 2 (5.00) |
Brodalumab, n (%) | 2 (5.00) |
Bimekizumab, n (%) | 1 (2.50) |
Anti-IL-12/23 agents | |
Ustekinumab, n (%) | 4 (10.00) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Fiorillo, G.; Ibba, L.; Gargiulo, L.; Narcisi, A.; Costanzo, A.; Valenti, M. Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study. J. Pers. Med. 2024, 14, 186. https://doi.org/10.3390/jpm14020186
Fiorillo G, Ibba L, Gargiulo L, Narcisi A, Costanzo A, Valenti M. Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study. Journal of Personalized Medicine. 2024; 14(2):186. https://doi.org/10.3390/jpm14020186
Chicago/Turabian StyleFiorillo, Giovanni, Luciano Ibba, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, and Mario Valenti. 2024. "Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study" Journal of Personalized Medicine 14, no. 2: 186. https://doi.org/10.3390/jpm14020186
APA StyleFiorillo, G., Ibba, L., Gargiulo, L., Narcisi, A., Costanzo, A., & Valenti, M. (2024). Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study. Journal of Personalized Medicine, 14(2), 186. https://doi.org/10.3390/jpm14020186